Recombinant Human FPRP/PTGFRN Fc Chimera Protein, CF

2 μg/lane of Recombinant Human FPRP/PTGFRN Fc Chimera Protein (Catalog # 10433-FP) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 120-140 kDa and 240-280 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human FPRP/PTGFRN Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human FPRP/PTGFRN Fc Chimera (Catalog # 10433-FP) is immobilized at 5 µg/mL (100 µL/well), Biotinylated Recombinant Human CD9 Fc Chimera binds with an ED₅₀ of 3-18 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human FPRP/PTGFRN protein
  

  Human FPRP/PTGFRN (Arg22-Lys830) Accession # Q9P2B2.2	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q9P2B2.2
• N-terminal Sequence: Arg22
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 117 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 120-140 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human FPRP/PTGFRN Fc Chimera Protein, CF

• CD315
• CD9P-1
• FPRP
• PTGFRN

Background

Prostoglandin F2 receptor negative regulator (PTGFRN), also known as CD9P-1, EWI-F, and CD315, is an integral type I transmembrane glycoprotein expressed on subsets of cells in ovary, uterus, lung, and heart (1-4). PTGFRN is a member of the Glu-Trp-Ile (EWI) subfamily within the Ig superfamily of molecules. The extracellular domain (ECD) of mature human PTGFRN contains six Ig-like C2-type domains and an EWI motif that acts as binding sites for actin-linking ezrin-radixin-moesin (ERM) proteins (1). The ECD of human PTGFRN shares 90% and 89% amino acid identity with mouse and rat PTGFRN, respectively. PTGFRN forms complexes with tetraspanins CD9 and CD81, linking these molecules to the intracellular actin cytoskeleton and regulating cell motility and polarity (1, 2). Increased expression of CD9 and CD81 inhibits the HEK/PTGFRN cell motility on collagen-I (3). In addition, PTGFRN expression positively correlates with the metastatic status of hLT and the upregulation of PTGFRN expression could be a mechanism involved in the loss of CD9 in solid tumors, such as in lung cancer (4)

1. Sala-Valdes, M. et al. (2006) J Biol Chem. 281:19665.
2. Stipp, C. S. et al. (2001) J Biol Chem. 276:4853.
3. Chambrion, C. et al. (2010) PLoS One. 5:11219.
4. Guilmain, W. et al. (2011) Br. J Cancer. 104:496.

Bioinformatics

• Uniprot:
  • Q9P2B2.2()